secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001728117-24-000024
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board
--------------------------------------------------------------------------------

- Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.
- Skye Drynan appointed as Class III director; former Capital Group Partner and Senior BioPharma Analyst.
- Each new director receives $40,000 annual cash retainer and option for 230,000 shares vesting over three years.
- Dr. Nathan's guidance intended to support expansion of seralutinib clinical program into PH-ILD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/0001728117-24-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/goss-20240311.htm
  HTML page:      https://secwatch.observer/filing/0001728117-24-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer